Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two ...
Leerink analyst David Risinger notes AbbVie (ABBV) announced on November 11 that emraclidine’s pivotal Phase 2 trials, EMPOWER-1 and ...
AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback